Cover Image
市場調查報告書

早產兒視網膜症 : 開發中產品分析

Retinopathy Of Prematurity - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 255964
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
早產兒視網膜症 : 開發中產品分析 Retinopathy Of Prematurity - Pipeline Review, H1 2017
出版日期: 2017年04月28日 內容資訊: 英文 32 Pages
簡介

所謂早產兒視網膜症(ROP)是阻礙早產兒視網膜血管發達的疾病。一般雙眼皆有可能出現,是幼兒期失明和長期性視力降低最常見的要素。早產兒視網膜症發病的風險要素有早產和出生體重超低,多胎生產等。

本報告提供全球各國治療早產兒視網膜症所用的開發中產品之開發情形相關分析,提供您送交開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查結果。

目錄

簡介

  • 分析範圍

早產兒視網膜症概要

治療藥的開發

  • 早產兒視網膜症轉動開發中產品:概要
  • 早產兒視網膜症治療藥:各企業
  • 早產兒視網膜症治療藥:開發中的產品一覽(各企業)

早產兒視網膜症:治療藥的評估

  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

早產兒視網膜症開發治療藥的企業

  • Biomar Microbial Technologies
  • F. Hoffmann-La Roche Ltd.
  • Recordati SpA

藥物簡介

暫停中的計劃

早產兒視網膜症相關的產品開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9216IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinopathy Of Prematurity - Pipeline Review, H1 2017, provides an overview of the Retinopathy Of Prematurity (Ophthalmology) pipeline landscape.

Retinopathy of prematurity (ROP) is a disease that affects immature vasculature in the eyes of premature babies. This disorder which usually develops in both eyes is one of the most common causes of visual loss in childhood and can lead to lifelong vision impairment and blindness Risk factors for the development of ROP include prematurity, extremely low-birth-weight, and multiple births.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinopathy Of Prematurity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinopathy Of Prematurity (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 2 and 2 respectively.

Retinopathy Of Prematurity (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinopathy Of Prematurity (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinopathy Of Prematurity (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinopathy Of Prematurity (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinopathy Of Prematurity (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinopathy Of Prematurity - Overview
    • Retinopathy Of Prematurity - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Retinopathy Of Prematurity - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinopathy Of Prematurity - Companies Involved in Therapeutics Development
    • Biomar Microbial Technologies
    • F. Hoffmann-La Roche Ltd
    • Recordati SpA
  • Retinopathy Of Prematurity - Drug Profiles
    • IB-09A0133 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • propranolol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • R-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranibizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Oncology and Diabetic Retinopathy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Retinopathy of Prematurity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinopathy Of Prematurity - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Retinopathy Of Prematurity, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H1 2017
  • Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Retinopathy Of Prematurity - Pipeline by Recordati SpA, H1 2017
  • Retinopathy Of Prematurity - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Retinopathy Of Prematurity, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top